Allogene Therapeutics ALLO Business Segments — Loss before income taxes
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Allogene Therapeutics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's business segments — loss before income taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's business segments — loss before income taxes?
- Allogene Therapeutics (ALLO) reported business segments — loss before income taxes of -$47.72M in Q4 2025.
- How has Allogene Therapeutics's business segments — loss before income taxes changed year-over-year?
- Allogene Therapeutics's business segments — loss before income taxes increased by 25.8% year-over-year, from -$64.29M to -$47.72M.
- What is the long-term trend for Allogene Therapeutics's business segments — loss before income taxes?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — loss before income taxes has grown at a -23.6% compound annual growth rate (CAGR), from -$327.27M to -$190.89M.
- What does business segments — loss before income taxes mean?
- This metric represents the pre-tax financial performance of a specific business segment, calculated as segment revenue minus segment operating expenses. It serves as a primary indicator of the segment's operational profitability or burn rate before accounting for tax obligations. Investors use this to evaluate the economic viability and cost-efficiency of specific product lines or business units within the broader corporate structure.